IACRLRD 2019

ML01 Translating DNA Repair for Targeting Cancers Prof. Kyungjae Myung UNIST / Institute for Basic Science, Korea CV

ML02 Biological Heterogeneity of AML: Implications for Prognosis and Treatment Prof. Clara Bloomfield The Ohio State University, USA CV

ML03 Approaching Survival of the General Population: The Results of CML Study IV in the Global Context Prof. Rüdiger Hehlmann Heidelberg University, Germany CV

ML04 New Models of Human Leukemia Dr. Connie Eaves British Columbia Cancer Agency, Canada CV

ML05 Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes Prof. David G. Maloney Fred Hutchinson Cancer Research Center, USA CV

ML06 Leukemia Stem Cell and Bone Marrow Microenvironment Interactions Prof. Ravi Bhatia The University of Alabama at Birmingham, USA CV

ML07 Understanding Evolution and Outcomes in Myeloproliferative Neoplasms Dr. Jyoti Nangalia Wellcome Sanger Institute, UK CV

KS Infectious Origins of Some Leukemias & What To Do Dr. Robert C. Gallo University of Maryland, USA CV

SY01-1 Using HTLV-1/BLV Genomics to Understand Adult T-cell Leukemia Dr. Anne Van den Broeke Jules Bordet Institute - ULB, Belgium

SY01-2 A Novel Epigenetic Drug against Adult T-cell Leukemia Prof. Toshiki Watanabe The University of Tokyo, Japan CV

SY01-3 Can We Cure Adult T Cell Leukemia/Lymphoma? Prof. Ali Bazarbachi American University of Beirut-Medical Center, Lebanon CV

SY02-1 DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation Prof. Myunggon Ko Ulsan National Institute of Science and Technology, Korea CV

SY02-2 Iron Toxicity in MDS Prof. Daniela Cilloni University of Torino, Italy CV

SY02-3 DDX41 Mutations in Myelodysplastic Syndrome Prof. Je-Hwan Lee University of Ulsan, Korea CV

SY02-4 Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy Prof. Michael Lübbert University of Freiburg Medical Center, Germany CV

LS01 TBD Prof. Richard Clark University of Liverpool, UK CV

SY03-1 The Rapidly Evolving Landscape in AML Prof. Gert Ossenkoppele Amsterdam University Medical Center, location VUMC, The Netherlands CV

SY03-2 Curative Treatment Options for Older Patients with AML Prof. Hervé Dombret Saint-Louis Institute for Research/ University of Paris, France CV

SY03-3 Development of A Novel FLT3 Inhibitor Prof. Hitoshi Kiyoi Nagoya University, Japan CV

SY03-4 Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML Prof. Jeffrey Tyner Oregon Health & Science University, USA CV

SY04-1 Next Generation Sequencing for Chronic Myeloid Leukemia Prof. Susan Branford Centre for Cancer Biology, SA Pathology, Australia CV

SY04-2 New Horizon for CML Therapy: Treatment Discontinuation (TFR) Prof. Giuseppe Saglio University of Torino, Italy CV

SY04-3 TBD Prof. Michael Mauro Memorial Sloan Kettering Cancer Center, USA CV

SY04-4 Allogeneic Stem Cell Transplantation in CML Prof. Eduardo Olavarria Imperial College London, UK CV

SY05-1 Clinical and Biological Significance of RNA Editing Defect in Myeloma Prof. Wee Joo Chng National University Health System, Singapore CV

SY05-2 Current Approaches and Future Perspectives in the Treatment of Newly Diagnosed Myeloma Patients Prof. Roberto Mina University of Torino, Italy CV

SY05-3 MRD: A Pitfall Between Next Generation Flow and Next Generation Sequencing Prof. Dong Soon Lee Seoul National University, Korea CV

SY06-1 Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model Prof. Itaru Kato Kyoto University, Japan CV

SY06-2 Targeting Cell Adhesion-mediated Resistance in ALL Prof. Yong-Mi Kim University of Southern California, USA CV

SY06-3 Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia Prof. Dieter Hoelzer Onkologikum Frankfurt, Germany CV

SY06-4 TBD Prof. Françoise Huguet University Institute of Cancer, France CV

LS02 Cutting Edge of Molecular Target Therapy and Therapeutic Strategies in CML Prof. Yosuke Minami National Cancer Center Hospital East, Japan CV

SY07-1 Understanding and Targeting the Stem Cell Origins of MDS and AML Prof. Ulrich Steidl Albert Einstein College of Medicine - Montefiore Medical Center, USA CV

SY07-2 Genetics and Mechanisms of Chemotherapy Resistance in ALL Prof. Adolfo Ferrando Columbia University, USA CV

SY07-3 TBD Prof. Seishi Ogawa Kyoto University, Japan

SY07-4 Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution Prof. Semin Lee Ulsan National Institute of Science and Technology, Korea CV

SY08-1 Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia Prof. Gianluca Gaidano University of Eastern Piedmont, Italy CV

SY08-2 TBD Prof. Wei Xu Jiangsu Province Hospital, China CV

SY08-3 Management of NK/T-cell Lymphoma Prof. Seok Jin Kim Samsung Medical Center, Korea CV

SY08-4 TBD Prof. Richard Larson The University of Chicago, USA CV

SY09-1 2020 Clinical, Laboratory, Molecular and Bone Marrow (CLMB) Classification and Treatment Options of Myeloproliferative Neoplasms Prof. Jan Jacques Michiels Goodheart Institute and Foundation, The Netherlands CV